Ornipressin
Also known as: 8-ornithine vasopressin, Ornipressin (M‑2), Ornipressin acetate, POR-8, Porselin, Vasopressin ornithine-8
Source Ornipressin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Ornipressin is a synthetic analog of vasopressin designed for strong V1‑receptor mediated vasoconstriction. It has been investigated for use in acute hypotension, hemorrhagic shock, and as a topical hemostatic agent, but is not widely approved for clinical use.
Mechanism of Action
Agonist at V1 vasopressin receptors causing potent vasoconstriction and increased peripheral vascular resistance.
Routes of Administration
Goals & Uses
- Acute hypotension managementHemodynamic SupportModerate
- Local vasoconstriction adjunct to anesthesiaSurgical/anestheticHigh
- Control of variceal bleedingGastroenterologyModerate
- Reduction of intraoperative blood lossSurgicalModerate
- Control of intra‑operative bleedingHemostasisLow
- Management of circulatory shockCritical CareLow
Contraindications
- Hypertension (uncontrolled)CardiovascularModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Severe cardiovascular diseaseCardiovascularHigh
- Coronary artery diseaseCardiovascularHigh
- Hypersensitivity to ornipressin or vasopressin analoguesAllergy/ImmunologyHigh
- Peripheral vascular diseaseVascularModerate
- Severe peripheral vascular diseaseVascularHigh
Adverse Effects
- HypertensionCardiovascularCommonHigh blood pressure
- Ischemic complicationsVascularUncommon
- Nausea and vomitingGastrointestinalUncommon
- Pallor and peripheral ischemiaVascularCommon
- Tissue necrosis at injection siteLocal/DermatologicalUncommon
- Cardiac arrhythmiasCardiovascularUncommon
- BradycardiaCardiovascularCommon
Drug Interactions
- Halogenated inhalation anesthetics (e.g., halothane)High
- Beta-blockersModerate
- Tricyclic antidepressantsModerate
- Other vasoconstrictors (e.g., norepinephrine, phenylephrine)High
- NSAIDsLowMay increase renal risk in susceptible patients
- Vasodilators (e.g., nitroglycerin)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Hepatic impairment/cirrhosisOrgan ImpairmentRelative
- Elderly patientsAgeRelative
- PediatricsAgeRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization; used in experimental protocols.
- United StatesUnapprovedNot approved by FDA; available only for research.
- United KingdomUnknownLimited information on current UK regulatory status post-Brexit; historically available in some European markets.
Approved in several European countries and other jurisdictions for use as a local vasoconstrictor adjunct. Not FDA-approved in the United States. Used in clinical practice in Europe, Latin America, and parts of Asia.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Ornipressin?
Ornipressin is a synthetic analog of vasopressin designed for strong V1‑receptor mediated vasoconstriction. It has been investigated for use in acute hypotension, hemorrhagic shock, and as a topical hemostatic agent, but is not widely approved for clinical use.
What is Ornipressin used for?
Ornipressin is educationally associated with: Acute hypotension management, Local vasoconstriction adjunct to anesthesia, Control of variceal bleeding, Reduction of intraoperative blood loss, Control of intra‑operative bleeding, Management of circulatory shock. Educational only — not medical advice.
How is Ornipressin administered?
Recorded routes of administration: Intramuscular, Intravenous, Local Infiltration, Subcutaneous, Topical.
What are the potential side effects of Ornipressin?
Reported adverse effects include: Hypertension, Ischemic complications, Nausea and vomiting, Pallor and peripheral ischemia, Tissue necrosis at injection site, Cardiac arrhythmias, Bradycardia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Ornipressin?
Recorded contraindications: Hypertension (uncontrolled), Pregnancy, Severe cardiovascular disease, Coronary artery disease, Hypersensitivity to ornipressin or vasopressin analogues, Peripheral vascular disease, Severe peripheral vascular disease. Consult a qualified clinician before use.